{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:45:05Z","timestamp":1792154705890,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,6,6]],"date-time":"2010-06-06T00:00:00Z","timestamp":1275782400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm World Sci"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s11096-010-9398-5","type":"journal-article","created":{"date-parts":[[2010,6,5]],"date-time":"2010-06-05T05:48:08Z","timestamp":1275716888000},"page":"503-511","source":"Crossref","is-referenced-by-count":38,"title":["Patterns of clozapine prescribing in a mental health service in New Zealand"],"prefix":"10.1007","volume":"32","author":[{"given":"Jeff","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Janl\u00f6v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,6]]},"reference":[{"key":"9398_CR1","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders fourth edition. Washington DC: American Psychiatric Association; 1994."},{"key":"9398_CR2","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Washington DC: American Psychiatric Association; 2004."},{"key":"9398_CR3","doi-asserted-by":"crossref","unstructured":"Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Schizophrenia and Related Disorders. Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust NZ J Psychiatry. 2005;39(1\u20132):1\u201330.","DOI":"10.1111\/j.1440-1614.2005.01516.x"},{"key":"9398_CR4","unstructured":"National Collaborating Centre for Mental Health. Schizophrenia: core interventions in the treatment of schizophrenia in primary and secondary care. Clinical guideline 1. London: National Institute for Clinical Excellence; 2002."},{"issue":"9657","key":"9398_CR5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31\u201341.","journal-title":"Lancet"},{"issue":"5 I","key":"9398_CR6","first-page":"688","volume":"32","author":"S Hiltgen","year":"2006","unstructured":"Hiltgen S, Mantelet S, Pinabel F, Enjaume F. Retrospective study of clozapine use in Ile-de-France. [Published in French as \u00c9tude r\u00e9trospective sur l\u2019utilisation de la clozapine en \u00cele-de-France] Encephale. 2006;32(5 Pt 1):688\u201396.","journal-title":"E?tude re?trospective sur l\u2019utilisation de la clozapine en I?le-de-France"},{"issue":"9","key":"9398_CR7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789\u201396.","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"9398_CR8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archpsyc.58.10.965","volume":"58","author":"JM Kane","year":"2001","unstructured":"Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry. 2001;58(10):965\u201372.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"9398_CR9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","volume":"32","author":"SW Lewis","year":"2006","unstructured":"Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32(4):715\u201323.","journal-title":"Schizophr Bull"},{"issue":"4","key":"9398_CR10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","volume":"163","author":"JP McEvoy","year":"2006","unstructured":"McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600\u201310.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"9398_CR11","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4088\/JCP.v66n0905","volume":"66","author":"DC Henderson","year":"2005","unstructured":"Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66(9):1116\u201321.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"9398_CR12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/schbul\/17.2.247","volume":"17","author":"A Safferman","year":"1991","unstructured":"Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull. 1991;17(2):247\u201361.","journal-title":"Schizophr Bull"},{"key":"9398_CR13","unstructured":"Novartis New Zealand Ltd. CLOZARIL\u00ae Data Sheet. Wellington, New Zealand: Medsafe (New Zealand Medicines and Medical Devices Safety Authority); 2009 [updated 2009 June 2009; cited 14\/12\/2009]. http:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/c\/Clozariltab.htm ."},{"key":"9398_CR14","unstructured":"Douglas Pharmaceuticals Ltd. CLOPINE\u00ae Data Sheet. Wellington, New Zealand.: Medsafe (New Zealand Medicines and Medical Devices Safety Authority); 2009 [updated 2009 December 2008; cited 14\/12\/2009]. http:\/\/www.medsafe.govt.nz\/profs\/datasheet\/c\/Clopinetab.htm ."},{"issue":"2","key":"9398_CR15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/archpsyc.61.2.143","volume":"61","author":"I Melle","year":"2004","unstructured":"Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S, et al. Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch Gen Psychiatry. 2004;61(2):143\u201350.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"9398_CR16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1192\/bjp.187.3.248","volume":"187","author":"W Gaebel","year":"2005","unstructured":"Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry. 2005;187(3):248\u201355.","journal-title":"Br J Psychiatry"},{"key":"9398_CR17","unstructured":"National Institute for Clinical Excellence (NICE) Guidelines in the UK. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care National Institute for Clinical Excellence (NICE) guidelines in the UK. 2002. p. 1\u2013264."},{"key":"9398_CR18","unstructured":"Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry. 2005;50(13):7S\u201357S."},{"key":"9398_CR19","unstructured":"Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. J Clin Psychiatry. 2003;64(Suppl 12):2\u201397."},{"issue":"2","key":"9398_CR20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/oxfordjournals.schbul.a007071","volume":"30","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004;30(2):193\u2013217.","journal-title":"Schizophr Bull"},{"issue":"4","key":"9398_CR21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4088\/JCP.v65n0408","volume":"65","author":"AL Miller","year":"2004","unstructured":"Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65(4):500\u20138.","journal-title":"J Clin Psychiatry"},{"key":"9398_CR22","unstructured":"Walker RA, Martin S. Demographic profile for Waitemata District health board: an analysis of 2006 census. Auckland: Watemata District Health Board; 2007."},{"key":"9398_CR23","unstructured":"Bailey D. A users guide to the Mental Health (Compulsory Assessment and Treatment) Act. Wellington: Department of Health; 1992."},{"issue":"1","key":"9398_CR24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","volume":"45","author":"RJ Baldessarini","year":"1988","unstructured":"Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988;45(1):79\u201391.","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"9398_CR25","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4088\/JCP.v65n1013","volume":"65","author":"R Ganguly","year":"2004","unstructured":"Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998\u20132000. J Clin Psychiatry. 2004;65(10):1377\u201388.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"9398_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hup.821","volume":"22","author":"YT Xiang","year":"2007","unstructured":"Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Clinical correlates of clozapine prescription for schizophrenia in China. Hum Psychopharmacol. 2007;22(1):17\u201325.","journal-title":"Hum Psychopharmacol"},{"key":"9398_CR27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2710.2002.00443.x","volume":"27","author":"XS Ren","year":"2002","unstructured":"Ren XS, Kazis LE, Lee AF, Hamed A. Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. J Clin Pharm Therapeut. 2002;27:441\u201351.","journal-title":"J Clin Pharm Therapeut"},{"issue":"10","key":"9398_CR28","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/00048670701579066","volume":"41","author":"A Wheeler","year":"2007","unstructured":"Wheeler A. Sociodemographic, functional and clinical correlates in outpatients with schizophrenia: comparison with affective disorders. Aust N Z J Psychiatry. 2007;41(10):809\u201318.","journal-title":"Aust N Z J Psychiatry"},{"key":"9398_CR29","doi-asserted-by":"crossref","unstructured":"Dickey B, Normand SL, Weiss RD, Drake RE, Azeni H. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv. 2002;53(7):861\u20137.","DOI":"10.1176\/appi.ps.53.7.861"},{"issue":"5","key":"9398_CR30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1600-0447.2007.01095.x","volume":"116","author":"S Leucht","year":"2007","unstructured":"Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatry Scand. 2007;116(5):317\u201333.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"9398_CR31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.nmd.0000130135.78017.96","volume":"192","author":"J Sokal","year":"2004","unstructured":"Sokal J, Messias E, Dickerson FB, Kreyenbuhl J, Brown CH, Goldberg RW, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis. 2004;192(6):421\u20137.","journal-title":"J Nerv Ment Dis"},{"issue":"1","key":"9398_CR32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4088\/JCP.v64n0107","volume":"64","author":"DM Taylor","year":"2003","unstructured":"Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003;64(1):30\u20134.","journal-title":"J Clin Psychiatry"},{"key":"9398_CR33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11096-006-9063-1","volume":"29","author":"WJ Broekman","year":"2007","unstructured":"Broekman WJ, de Groot IW, van Harten PN. Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics\u2013\u2013a European study. Pharm World Sci. 2007;29:126\u20131230.","journal-title":"Pharm World Sci"},{"issue":"4","key":"9398_CR34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/10398560802189896","volume":"16","author":"A McKean","year":"2008","unstructured":"McKean A, Vella-Brincat J, Begg E. Prescribing and monitoring clozapine in Christchurch. Aust Psychiatry. 2008;16(4):263\u20137.","journal-title":"Aust Psychiatry"},{"key":"9398_CR35","doi-asserted-by":"crossref","unstructured":"Conley RR, Kelly DL, Lambert TJ, Love RC. Comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatr Serv. 2005;56(3):320\u20133.","DOI":"10.1176\/appi.ps.56.3.320"},{"issue":"4","key":"9398_CR36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/jcp.0b013e3180d0a6d4","volume":"27","author":"O Agid","year":"2007","unstructured":"Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol. 2007;27(4):369\u201373.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"9398_CR37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00023210-200721040-00002","volume":"21","author":"R Kerwin","year":"2007","unstructured":"Kerwin R. When should clozapine be initiated in schizophrenia? Some arguments for and against earlier use of clozapine. CNS Drugs. 2007;21(4):267\u201378.","journal-title":"CNS Drugs"}],"container-title":["Pharmacy World & Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-010-9398-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-010-9398-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-010-9398-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T05:54:29Z","timestamp":1559368469000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-010-9398-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,6]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["9398"],"URL":"https:\/\/doi.org\/10.1007\/s11096-010-9398-5","relation":{},"ISSN":["0928-1231","1573-739X"],"issn-type":[{"value":"0928-1231","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,6]]}}}